Resource utilization and costs associated with insomnia treatment in patients with major depressive disorder

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 14, Issue 5, 2012, Pages

  Tian, Haijun ^a   Abouzaid, Safiya ^a   Gabriel, Susan ^a   Kahler, Kristijan H ^a   Kim, Edward ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CARBROMAL; ESTAZOLAM; ESZOPICLONE; ETHCHLORVYNOL; FLURAZEPAM; PENTOBARBITAL; QUAZEPAM; RAMELTEON; SECBUTABARBITAL; SECOBARBITAL; SEROTONIN UPTAKE INHIBITOR; TEMAZEPAM; TRIAZOLAM; ZALEPLON; ZOLPIDEM TARTRATE;

ADULT; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DRUG COST; EMERGENCY WARD; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITALIZATION COST; HUMAN; INSOMNIA; JOB PERFORMANCE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRESCRIPTION; RISK FACTOR; SENSITIVITY ANALYSIS;

EID: 84869406690     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.12m01374     Document Type: Article

References (38)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000.
2. Hasin DS, Goodwin RD, Stinson FS, et al. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry. 2005;62(10):1097-1106. PubMed doi:10.1001/archpsyc.62.10.1097 Show Abstract Show Abstract
3. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 2003;64(12):1465-1475. PubMed doi:10.4088/JCP.v64n1211 Show Abstract Show Abstract
4. Stewart WF, Ricci JA, Chee E, et al. Cost of lost productive work time among US workers with depression. JAMA. 2003;289(23):3135-3144. PubMed doi:10.1001/jama.289.23.3135 Show Abstract Show Abstract
5. Work Group on Major Depressive Disorder. Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition. Washington, DC: American Psychiatric Association. 2010.
6. Knoth RL, Bolge SC, Kim E, et al. Effect of inadequate response to treatment in patients with depression. Am J Manag Care. 2010;16(8):e188-e196. PubMed Show Abstract Show Abstract
7. Gibson TB, Jing Y, Smith Carls G, et al. Cost burden of treatment resistance in patients with depression. Am J Manag Care. 2010;16(5):370-377. PubMed Show Abstract Show Abstract
8. Tsuno N, Besset A, Ritchie K. Sleep and depression. J Clin Psychiatry. 2005;66(10):1254-1269. PubMed doi:10.4088/JCP.v66n1008 Show Abstract Show Abstract
9. Fava M. Daytime sleepiness and insomnia as correlates of depression. J Clin Psychiatry. 2004;65(suppl 16):27-32. PubMed Show Abstract Show Abstract
10. Nierenberg AA, Keefe BR, Leslie VC, et al. Residual symptoms in depressed patients who respond acutely to fluoxetine. J Clin Psychiatry. 1999;60(4):221-225. PubMed doi:10.4088/JCP.v60n0403 Show Abstract Show Abstract
11. Nelson JC, Portera L, Leon AC. Residual symptoms in depressed patients after treatment with fluoxetine or reboxetine. J Clin Psychiatry. 2005;66(11):1409-1414. PubMed doi:10.4088/JCP.v66n1110 Show Abstract Show Abstract
12. Léger D, Bayon V. Societal costs of insomnia. Sleep Med Rev. 2010;14(6):379-389. PubMed doi:10.1016/j.smrv.2010.01.003 Show Abstract Show Abstract
13. Aǧargün MY, Kara H, Solmaz M. Sleep disturbances and suicidal behavior in patients with major depression. J Clin Psychiatry. 1997;58(6):249-251. PubMed doi:10.4088/JCP.v58n0602 Show Abstract Show Abstract
14. Spitzer RL, Kroenke K, Linzer M, et al. Health-related quality of life in primary care patients with mental disorders: results from the PRIME-MD 1000 study. JAMA. 1995;274(19):1511-1517. PubMed doi:10.1001/jama.1995.03530190025030 Show Abstract Show Abstract
15. Léger D, Guilleminault C, Bader G, et al. Medical and socio-professional impact of insomnia. Sleep. 2002;25(6):625-629. PubMed Show Abstract Show Abstract
16. Overland S, Glozier N, Sivertsen B, et al. A comparison of insomnia and depression as predictors of disability pension: the HUNT study. Sleep. 2008;31(6):875-880. PubMed Show Abstract Show Abstract
17. Gartlehner G, Gaynes BN, Hansen RA, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med. 2008;149(10):734-750. PubMed Show Abstract Show Abstract
18. National Institutes of Health. National Institutes of Health State of the Science Conference Statement on Manifestations and Management of Chronic Insomnia in Adults, June 13-15, 2005. Sleep. 2005;28(9):1049-1057. PubMed Show Abstract Show Abstract
19. Pollack M, Seal B, Joish VN, et al. Insomnia-related comorbidities and economic costs among a commercially insured population in the United States. Curr Med Res Opin. 2009;25(8):1901-1911. PubMed doi:10.1185/03007990903035505 Show Abstract Show Abstract
20. Sarsour K, Kalsekar A, Swindle R, et al. The association between insomnia severity and healthcare and productivity costs in a health plan sample. Sleep. 2011;34(4):443-450. PubMed Show Abstract Show Abstract
21. Greenberg P, Corey-Lisle PK, Birnbaum H, et al. Economic implications of treatment-resistant depression among employees. Pharmacoeconomics. 2004;22(6):363-373. PubMed doi:10.2165/00019053-200422060-00003 Show Abstract Show Abstract
22. Whooley MA, Kiefe CI, Chesney MA, et al; CARDIA Study. Depressive symptoms, unemployment, and loss of income: the CARDIA Study. Arch Intern Med. 2002;162(22):2614-2620. PubMed doi:10.1001/archinte.162.22.2614 Show Abstract Show Abstract
23. Birnbaum HG, Ben-Hamadi R, Greenberg PE, et al. Determinants of direct cost differences among US employees with major depressive disorders using antidepressants. Pharmacoeconomics. 2009;27(6):507-517. PubMed doi:10.2165/00019053-200927060-00006 Show Abstract Show Abstract
24. Birnbaum HG, Ben-Hamadi R, Kelley D, et al. Assessing the relationship between compliance with antidepressant therapy and employer costs among employees in the United States. J Occupat Environ Med. 2010;52(2):115-124. PubMed
25. US Food and Drug Administration. US Department of Health and Human Services. Drugs: Sleep Disorder (Sedative-Hypnotic) Drug Information. http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm101557.htm. Updated March 2, 2010. Accessed June 20, 2012.
26. Ozminkowski RJ, Wang S, Walsh JK. The direct and indirect costs of untreated insomnia in adults in the United States. Sleep. 2007;30(3):263-273. PubMed Show Abstract Show Abstract
27. Asche CV, Joish VN, Camacho F, et al. The direct costs of untreated comorbid insomnia in a managed care population with major depressive disorder. Curr Med Res Opin. 2010;26(8):1843-1853. PubMed doi:10.1185/03007995.2010.488037 Show Abstract Show Abstract
28. O'Sullivan AK, Sullivan J, Higuchi K, et al. Health care utilization and costs for cystic fibrosis patients with pulmonary infections. Manag Care. 2011;20(2):37-44. PubMed Show Abstract Show Abstract
29. Asche CV, Singer ME, Jhaveri M, et al. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. J Manag Care Pharm. 2010;16(9):703-712. PubMed Show Abstract Show Abstract
30. US Bureau of Labor Statistics. Establishment Data: Historical Hours and Earnings. 2012. ftp://ftp.bls.gov/pub/suppl/empsit.ceseeb2.txt. Accessed July 25, 2012.
31. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619. PubMed doi:10.1016/0895-4356(92)90133-8 Show Abstract Show Abstract
32. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383. PubMed doi:10.1016/0021-9681(87)90171-8 Show Abstract Show Abstract
33. Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. New York, NY: John Wiley & Sons, Inc; 2000. doi:10.1002/0471722146
34. Buntin MB, Zaslavsky AM. Too much ado about two-part models and transformation? Comparing methods of modeling Medicare expenditures. J Health Econ. 2004;23(3):525-542. PubMed doi:10.1016/j.jhealeco.2003.10.005 Show Abstract Show Abstract
35. Salo P, Sivertsen B, Oksanen T, et al. Insomnia symptoms as a predictor of incident treatment for depression: prospective cohort study of 40,791 men and women. Sleep Med. 2012;13(3):278-284. PubMed doi:10.1016/j.sleep.2011.06.022 Show Abstract Show Abstract
36. van Mill JG, Hoogendijk WJ, Vogelzangs N, et al. Insomnia and sleep duration in a large cohort of patients with major depressive disorder and anxiety disorders. J Clin Psychiatry. 2010;71(3):239-246. PubMed doi:10.4088/JCP.09m05218gry Show Abstract Show Abstract
37. Bjørngaard JH, Bjerkeset O, Romundstad P, et al. Sleeping problems and suicide in 75,000 Norwegian adults: a 20 year follow-up of the HUNT I study. Sleep. 2011;34(9):1155-1159. PubMed Show Abstract Show Abstract
38. Corey-Lisle PK, Birnbaum HG, Greenberg PE, et al. Identification of a claims data "signature" and economic consequences for treatment-resistant depression. J Clin Psychiatry. 2002;63(8):717-726. PubMed doi:10.4088/JCP.v63n0810 Show Abstract Show Abstract